Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Middle East Conflict Impacts Australia and New Zealand Businesses 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
NEWARK, Calif., May 01, 2018 -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Tuesday, May 8, 2018 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2018 and to provide a business update.
Conference Call Details
To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13678369. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events.
About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof of concept in PBC. CymaBay is currently planning to advance development of seladelpar into Phase 3 for PBC and Phase 2 for NASH.
For additional information about CymaBay visit www.cymabay.com.
Contact:
Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568
[email protected]
